Related Experiment Video
Updated: Dec 20, 2025
10:20
Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice
Published on: January 16, 2013
25.8K
RNA-Binding Proteins in Pulmonary Hypertension
Hui Zhang1, R Dale Brown1, Kurt R Stenmark1
1Cardiovascular Pulmonary Research Laboratories, Departments of Pediatrics and Medicine, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
International Journal of Molecular Sciences
|May 30, 2020
Summary
This review explores RNA-binding proteins (RBPs) in pulmonary hypertension (PH). Understanding RBPs
Area of Science:
- Pulmonary hypertension (PH) research
- Gene regulation mechanisms
- Cardiovascular disease pathophysiology
Background:
- Pulmonary hypertension (PH) involves vascular remodeling and altered gene expression.
- Current PH research primarily focuses on gene transcription, neglecting post-transcriptional regulation.
- Post-transcriptional alterations are crucial in other diseases, implicating RNA-binding proteins (RBPs).
Purpose of the Study:
- To review the role of dysregulated RBPs in PH pathophysiology.
- To highlight RBPs as potential therapeutic targets for PH.
- To bridge the knowledge gap regarding RBPs in PH.
Main Methods:
- Literature review of studies on gene expression in PH.
- Analysis of research on RBPs in other cardiovascular and inflammatory diseases.
- Synthesis of current knowledge on RBPs and non-coding RNA in PH.
Main Results:
- Dysregulated RBPs contribute to aberrant mRNA processing in PH.
- RBPs influence non-coding RNA expression, including microRNAs (miRNAs), in PH.
- The role of RBPs in PH pathogenesis is increasingly recognized.
Conclusions:
- RBPs are critical regulators of gene expression in PH.
- Targeting RBPs offers a promising avenue for novel PH therapies.
- Further research into RBPs is essential for advancing PH treatment strategies.
Related Concept Videos
01:30Pulmonary Hypertension: Classification and Pathogenesis
485
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
485
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
368
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
368
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
343
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
343
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
370
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
370
01:24Regulation of Angiogenesis and Blood Supply
3.2K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.2K
01:27Transducer Mechanism: Enzyme-Linked Receptors
3.7K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.7K